Qulipta (atogepant) is a prescription drug used daily for the preventive treatment of episodic migraine (with headaches occurring up to 14 days per month) in adults. Its mechanism, which involves blocking calcitonin gene-related peptide (CGRP) receptors, is focused on preventing the onset of migraine attacks. There are no off-label uses or additional approved therapeutic indications unrelated to migraines at this time.
Key Takeaways
Qulipta (atogepant) is a prescription drug used daily for the preventive treatment of episodic migraine (with headaches occurring up to 14 days per month) in adults.
The primary mechanism that the prescription medication uses to prevent the onset of migraine attacks involves blocking calcitonin gene-related peptide (CGRP) receptors in the brain. Preventing migraine attacks from occurring.
Qulipta (atogepant) may be used in combination with other medications. For example Qulipta (atogepant) may also be prescribed along with ibuprofen for pain relief as well as migraine prevention.
Qulipta Uses
Clinical trials and recent studies from the CADTH Canadian Drug Expert Committee (CDEC) noted that “Evidence from 3 clinical trials demonstrated that Qulipta reduced the mean number of days patients experienced migraines and headaches per month compared with placebo. The trials showed that Qulipta reduced migraine symptoms.”
Qulipta (ateogepant) has been known to be effective for:
The prevention of chronic migraines. It works by blocking CGRP, a substance in the brain that can make headaches last longer.
Qulipta and its drug atogepant does not have any other additional uses at this time. Additional trials and studies have not been performed to find additional uses.
Related: Qulipta Side Effects
Take Control of Rising Prescription Drug Costs With Drugmart.com Drugmart.com is the Canadian online prescription referral service that you can trust to help you tackle the high price of prescription drugs. We bring you savings right to your door. Shop now for prescription medication to begin saving on rising drug prices.
Sources
Canadian Agency for Drugs and Technologies in Health. (2023, June). Atogepant (Qulipta): CADTH reimbursement recommendation. CADTH. https://www.ncbi.nlm.nih.gov/books/NBK595348/
U.S. Food and Drug Administration. (n.d.). QULIPTA (atogepant) prescribing information. https://www.accessdata.fda.gov/spl/data/a313e1c3-0edb-4e39-b069-0c538f0c9424/a313e1c3-0edb-4e39-b069-0c538f0c9424.xml
Rizzoli, P., Marmura, M. J., Robblee, J., McVige, J., Sacco, S., Nahas, S. J., Ailani, J., Ferreira, R. D. A., Ma, J., Smith, J. H., Dabruzzo, B., & Ashina, M. (2024). Safety and tolerability of atogepant for the preventive treatment of migraine: A post hoc analysis of pooled data from four clinical trials. The Journal of Headache and Pain, 25(1), 35. https://doi.org/10.1186/s10194-024-01736-z
Related Articles
Qulipta Cost: With and Without Insurance (Guide)
On average, Qulipta (atogepant) can cost anywhere from $1,299 to $1,490.16 per full supply that’s not covered by insurance. Typically, that’s a 30-day supply of 60 milligram (mg) oral...
Qulipta and Weight Loss: What to Know
Qulipta (atogepant) trials showed that patients who took Qulipta against patients who took a placebo experienced a 7% decrease in body weight. More patients experience weight decrease when on the 10 mg...
Importing Prescription Drugs for Personal Use: Is the Importation of Drugs from Canada Safe?
Talk about the importation of drugs is frequently in the news. But what does that mean for Americans? Is importing prescription drugs for personal use legal?...
